期刊文献+

ELISA检测肿瘤相关抗原CA19-9的方法学评价 被引量:1

Methodological Evaluation of ELISA Assay for Tumor Related Antigen CA19-9
在线阅读 下载PDF
导出
摘要 对肿瘤相关抗原CA19-9酶联免疫法(ELISA法)进行方法学评价。选取各类标本204份,将本方法的灵敏度、特异性、阳性预测值、阴性预测值与电化学发光免疫分析(ECLIA)的进行比较并综合分析。本方法检测的灵敏度为52.5%,特异性为82.9%,阳性预测值为82.1%,阴性预测值为54.0%。以ECLIA为相对标准,相对灵敏度为100%,相对特异性为100%,相对符合率为100%,与ECLIA相关性显著,r2=0.9749。相关分析结果表明,ELISA与ECLIA相关性好。本方法试剂稳定,结果准确、可靠,有很高的特异性。 To evaluate the methodology of ELISA assay for CA19-9,204 serum samples were selected into this study. The sensitivity, specificity, positive predictive value, negative predictive value of this method was evalua- ted with compared reagent. The sensitivity of this method was 52.5% ,specificity was 82.9% ,PPV was 82.1% and NPV was 54.0%. When ECLIA was set as relative standard, the relative sensitivity, specificity and consis- tency were 100% , 100% and 100% respectively. The correlation coefficient was good and the relativity had sta- tistic significant different. The results indicate that the reagent used in this study is stable, and the measurement result is correct and reliable with high specificity.
出处 《标记免疫分析与临床》 CAS 2009年第5期294-295,共2页 Labeled Immunoassays and Clinical Medicine
基金 国家科技部863计划项目(2006AA02090206)
关键词 肿瘤相关抗原 CA19-9 酶联免疫法 电化学发光免疫法 消化道肿瘤 Tumor related antigen CA19-9 ELISA ECLIA Digestive tract cancer
  • 相关文献

参考文献3

  • 1Eskelinen M, Haglund U. Developments in serologic detection of human pancreatic adenocarcinoma [ J ]. Scand J Gastroenterol, 1999 (34) :833-844.
  • 2Rye P D, Bovin N V, Vlasova E V. Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens[ J]. Tumor Biol, 1998 (19) :390420.
  • 3许永春,李兆申,屠振兴.胰腺癌肿瘤标志物研究与应用进展[J].胰腺病学,2003,3(3):179-182. 被引量:6

二级参考文献35

  • 1Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer, 1994, 70: 481-486.
  • 2Furuya N, Kawa S, Hasebe O, et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer, 1996,73: 372-376.
  • 3Shimano T, Takami M. Pancreatic oneofetal antigen (POA),pancreatic cancer-associated antigen(PCAA). Nippon Rinsho,1999, 57(Suppl):452-454.
  • 4Rozenblum E, Schutte M, Goggins M, et al. Tumorsuppressive pathways in pancreatic carcinoma. Cancer Res,1997, 57: 1731-1734.
  • 5Apple SK, Hecht JR, Lewin DN, et al. Immunohistochemical evaluation of K-ras, p53 and HER-2/neu expression in hyperplastic dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol,1999, 30: 123-129.
  • 6Mizumoto K, Tanaka M. Genetic diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg, 2002, 9: 39-44.
  • 7Ha A, Watanabe H, Yamaguchi Y, et al. Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma. Pancreas, 2001, 23: 356-363.
  • 8Kimura W, Zhao B, Futakawa N, et al. Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas. Hepatogastroenterology, 1999, 46 :532-539.
  • 9Tateishi K, Tada M, Yamagata M, et al. Hight proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesion. Gut, 1999,45:737-740.
  • 10Ruggeri B, Zhang SY, Caamano J, et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.Oncogene, 1992, 75 1503-1511.

共引文献5

同被引文献40

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部